Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Biodesix, Inc. (NASDAQ:BDSX) have been given an average rating of “Moderate Buy” by the six research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $32.50.

Several brokerages have recently issued reports on BDSX. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Wall Street Zen upgraded Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th.

Biodesix Price Performance

Biodesix stock opened at $9.93 on Tuesday. Biodesix has a 1 year low of $3.44 and a 1 year high of $20.40. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a 50 day moving average price of $8.25 and a 200 day moving average price of $7.94. The company has a market cap of $79.04 million, a price-to-earnings ratio of -1.79 and a beta of 0.66.

Insider Buying and Selling at Biodesix

In other news, Director Jack W. Schuler acquired 82,465 shares of Biodesix stock in a transaction dated Thursday, January 22nd. The shares were acquired at an average cost of $10.96 per share, with a total value of $903,816.40. Following the purchase, the director directly owned 1,463,210 shares of the company’s stock, valued at approximately $16,036,781.60. This trade represents a 5.97% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders bought 182,465 shares of company stock valued at $2,084,616 and sold 1,947 shares valued at $15,868. 30.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Aberdeen Group plc purchased a new stake in Biodesix during the fourth quarter worth approximately $1,784,000. XTX Topco Ltd lifted its holdings in shares of Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after acquiring an additional 102,494 shares in the last quarter. Geode Capital Management LLC boosted its position in Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after purchasing an additional 2,235 shares during the period. Oracle Investment Management Inc. purchased a new stake in Biodesix during the 3rd quarter worth $113,000. Finally, Millennium Management LLC acquired a new stake in Biodesix in the 3rd quarter valued at $113,000. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.